These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 14559371)

  • 41. [Hormone replacement therapy and breast cancer].
    Mueck AO
    Med Monatsschr Pharm; 2002 Oct; 25(10):337-47. PubMed ID: 12404946
    [No Abstract]   [Full Text] [Related]  

  • 42. Hormone replacement therapy and breast cancer risk.
    Campagnoli C; Biglia N; Sismondi P
    JAMA; 1996 Apr; 275(15):1159-60. PubMed ID: 8609680
    [No Abstract]   [Full Text] [Related]  

  • 43. Hormone therapy and breast cancer: the press-release version of WHI study data.
    Pines A
    Climacteric; 2013 Apr; 16(2):222-5. PubMed ID: 23488525
    [No Abstract]   [Full Text] [Related]  

  • 44. Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.
    MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
    Breast Cancer Res Treat; 2010 Jan; 119(2):463-74. PubMed ID: 19424794
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Postmenopausal estrogens--opposed, unopposed, or none of the above.
    Willett WC; Colditz G; Stampfer M
    JAMA; 2000 Jan; 283(4):534-5. PubMed ID: 10659883
    [No Abstract]   [Full Text] [Related]  

  • 46. Understanding breast density and breast cancer risk.
    Peres J
    J Natl Cancer Inst; 2012 Sep; 104(18):1345-6. PubMed ID: 22984197
    [No Abstract]   [Full Text] [Related]  

  • 47. So far, victories are few as breast cancer patients sue Wyeth over hormone therapy.
    Twombly R
    J Natl Cancer Inst; 2007 Dec; 99(24):1828-9, 1835. PubMed ID: 18073368
    [No Abstract]   [Full Text] [Related]  

  • 48. Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Study.
    Palmer JR; Rosenberg L; Clarke EA; Miller DR; Shapiro S
    Am J Epidemiol; 1991 Dec; 134(12):1386-95; discussion 1396-401. PubMed ID: 1663701
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Endometrial cancer and hormone-replacement therapy in the Million Women Study.
    Beral V; Bull D; Reeves G;
    Lancet; 2005 Apr 30-May 6; 365(9470):1543-51. PubMed ID: 15866308
    [TBL] [Abstract][Full Text] [Related]  

  • 50. More about: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
    Magnusson C; Persson I; Adami HO
    J Natl Cancer Inst; 2000 Jul; 92(14):1183-4. PubMed ID: 10904095
    [No Abstract]   [Full Text] [Related]  

  • 51. Effects of hormone replacement therapy on mammographic findings.
    Bülbül NH; Ozden S; Dayicioglu V
    Arch Gynecol Obstet; 2003 Apr; 268(1):5-8. PubMed ID: 12673467
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
    van Leeuwen FE
    Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hormone replacement therapy and breast cancer risk.
    Melnikow J
    J Fam Pract; 1995 Nov; 41(5):501-2. PubMed ID: 7595271
    [No Abstract]   [Full Text] [Related]  

  • 54. Landmark hormone replacement therapy study stopped after finding more harms than benefits.
    Rollins G
    Rep Med Guidel Outcomes Res; 2002 Aug; 13(15):5-7. PubMed ID: 12553323
    [No Abstract]   [Full Text] [Related]  

  • 55. Postmenopausal estrogen-progestin therapy and breast cancer: a clinical response to epidemiological reports.
    Speroff L
    Climacteric; 2000 Mar; 3(1):3-12. PubMed ID: 11910607
    [No Abstract]   [Full Text] [Related]  

  • 56. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy--long-term follow-up of a Swedish cohort.
    Persson I; Yuen J; Bergkvist L; Schairer C
    Int J Cancer; 1996 Jul; 67(3):327-32. PubMed ID: 8707404
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population.
    Kerlikowske K; Miglioretti DL; Ballard-Barbash R; Weaver DL; Buist DS; Barlow WE; Cutter G; Geller BM; Yankaskas B; Taplin SH; Carney PA
    J Clin Oncol; 2003 Dec; 21(23):4314-21. PubMed ID: 14645420
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Update: estrogen and estrogen plus progestin therapy in the care of women at and after the menopause.
    Davey DA
    Womens Health (Lond); 2012 Mar; 8(2):169-89. PubMed ID: 22375720
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Million Women Study--is it believable?
    Farmer R
    Climacteric; 2005 Sep; 8(3):210-3. PubMed ID: 16390752
    [No Abstract]   [Full Text] [Related]  

  • 60. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy.
    Santen RJ; Pinkerton J; McCartney C; Petroni GR
    J Clin Endocrinol Metab; 2001 Jan; 86(1):16-23. PubMed ID: 11231971
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.